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Autophagy/ERAD(II)The Nε-amino group of lysine residues can be transiently modiﬁed by the addition of an acetyl group. Recog-
nized functions of Nε-lysine acetylation include regulation of activity, molecular stabilization and conforma-
tional assembly of a protein. For more than forty years lysine acetylation was thought to occur only in the
cytosol and nucleus. Targets included cytoskeletal-associated proteins as well as transcription factors, histone
proteins and proteins involved in DNA recombination and repair. However, in 2007 we reported that a type I
membrane protein involved in the pathogenesis of Alzheimer's disease was transiently acetylated on the ε
amino group of seven lysine residues while transiting along the secretory pathway. Surprisingly, the acetyla-
tion occurred in the lumen of the endoplasmic reticulum (ER) forcing us to reconsider old paradigms. Indeed,
if lysine acetylation can occur in the lumen of the ER, then all the essential biochemical elements of the reac-
tion must be available in the lumen of the organelle. Follow-up studies revealed the existence of ER-based
acetyl-CoA:lysine acetyltransferases as well as a membrane transporter that translocates acetyl-CoA from
the cytosol into the ER lumen. Large-scale proteomics showed that the list of substrates of the ER-based acet-
ylation machinery includes both transiting and resident proteins. Finally, genetic studies revealed that this
machinery is tightly linked to human diseases. Here, we describe these exciting ﬁndings as well as recent bio-
chemical and cellular advances, and discuss possible impact on both human physiology and pathology.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The ε-amino group of lysine residues can undergo different modiﬁ-
cations, including acetylation and other forms of acylation, sumoylation,
biotinylation, ubiquitylation and methylation. Although extensively
studied, the precise function(s) of the above modiﬁcations are still
largely unknown. Lysine acetylation was originally identiﬁed more
than forty years ago on the N-terminal tail of histone proteins, where
its transient status regulates the interactionwith chromatin and, as a re-
sult, DNA transcription [1]. Soon after, a large number of cytosolic and
nuclear proteins were reported to be transiently acetylated in one or
more lysine residues. In addition to histones, they include proteins in-
volved inDNA recombination and repair, transcription factors, cytoskel-
etal proteins, chaperones, signaling proteins, and several metabolic
enzymes [2,3]. Recognized functions of Nε-lysine acetylation include
regulation of activity, molecular stabilization and conformational as-
sembly of a protein [4]. The acetylation of the ε amino group of a lysineiversity ofWisconsin-Madison,
53705, USA. Tel.: +1 608 256
.
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l rights reserved.residue (more typically referred to as lysine acetylation) differs from
Nα-acetylation and O-acetylation. Nα-acetylation (also called N-terminal
acetylation) occurs on the α-amino group at the N-terminus of nascent
cytosolic proteins and is thought to be irreversible. It is mainly a
co-translational event and predominantly affects alanine, serine and me-
thionine residues; additionally it can also occur—albeit less often—on gly-
cine, threonine, valine and cysteine residues [5]. O-acetylation was
described on serine and threonine residues by two independent groups
while studying the virulence of bacteria of the genus Yersinia [6,7]. Al-
though the acetyltransferase activity of the bacterial effector Yersinia
outer protein J (YopJ) can target host proteins, an endogenous serine/
threonineO-acetyltransferase activity has not been identiﬁed inmamma-
lian cells. Both Nα- and O-acetylation are still poorly understood and will
not be discussed by this review.
From the biochemical perspective, lysine acetylation requires three
essential components: (1) an acceptor of the acetyl group (a protein
that has the appropriate lysine residues); (2) a donor of the acetyl
group (acetyl-CoA); and (3) an enzyme able to transfer the acetyl group
from the donor to the acceptor (an acetyl-CoA:lysine acetyltransferase
or simply called acetyltransferase). The above three components were
initially identiﬁedonly in the cytoplasmandnucleus; as a result, itwas as-
sumed that lysine acetylation could only occur in the cytosol or in the nu-
cleus [4,8]. However, in 2006 Schwer et al. reported the transient lysine
acetylation of the mitochondrial matrix protein acetyl-CoA synthetase
Box 1
Acetyl-CoA biosynthesis in the cytosol.
The generation of Acetyl-CoA in the cytosol requires conversion of
panthothenate (Vit B5) into Coenzyme A (CoA), a process that in-
volves five enzymatic steps [117]. The first reaction, phosphoryla-
tion of pantothenate to 4-phospho-pantothenate, appears to act
as the rate-limiting step and is catalyzed by pantothenate kinase
(Pank) (see Fig. 1). Mammals have four different genes encoding
different versions of Pank. PANK1 encodes Pank1α and Pankβ,
both found exclusively in the cytosol; PANK2 encodes a mitochon-
drial as well as at least one shorter cytosolic isoform (the catalytic
activity of two additional shorter isoforms has not been dem-
onstrated); PANK3 and PANK4 encode one cytosolic protein
each (the catalytic signature of Pank4 has not been proven).
Defects in Pank2 are associated with Hallervorden–Spatz syn-
drome (HSS), also known as pantothenate kinase-associated
neurodegeneration (PKAN), an autosomal recessive neurode-
generative disorder that affects the central nervous system
[118]. Genetic disruption of the common PANK gene, fumble
(fbl), in D. Melanogaster results in increased lethality as well
as infertility in the surviving animals [119], while disruption
of mouse Pank2 results in retinal degeneration and azoosper-
mia [120]. The possible involvement of the other Pank pro-
teins in human diseases is currently unknown.
The two main enzymes responsible for the biosynthesis of
acetyl-CoA in the cytosol are the ATP-citrate lyase (Acly) and
the acetyl-CoA synthetase (AceCS) (see Fig. 1). Homozygous
disruption of Acly in the mouse is lethal while heterozygous dis-
ruption is viable [121]. No information on the physiological as
well as pathological impact of AceCS is currently available;
however, genetic disruption of AceCS2 (also known as ACSS1)
which is exclusively found in the mitochondria, leads to defects
in thermoregulation and energy production as well as high de-
gree of mortality [122].
Mitochondria and peroxisome pathways that contribute to cy-
tosolic acetyl-CoA are described in the text.
687M. Pehar, L. Puglielli / Biochimica et Biophysica Acta 1833 (2013) 686–697[9], whereas in 2007 Costantini et al. reported the transient lysine acety-
lation of the nascent endoplasmic reticulum (ER)-based form of the
membrane protein β-site APP cleaving enzyme 1 (BACE1) [10]. After
these initialﬁndings, large-scale proteomic approaches reported that sev-
eral proteins localized in the mitochondrial matrix undergo Nε-lysine
acetylation [11,12]; their acetylation status regulates the metabolism of
the cell in response to nutrient availability [13]. Similarly, many mem-
brane and secreted proteins were reported to undergo transient lysine
acetylation in the ER lumen [14–16]. Finally, high-scale proteomics also
identiﬁed ER-resident chaperones and enzymes to be Nε-lysine acetylat-
ed in their luminal portion [12,16]. Therefore, what was once a cytosolic
and nuclear event now appears to be an essential component of mito-
chondria and ER functions as well.
2. A novel form of post-translational regulation in the ER
That Nε-lysine acetylation can occur in the lumen of the ER became
evident in 2007whenwe discovered that the ceramide-mediated regu-
lation of BACE1 metabolism required transient acetylation of the na-
scent protein in the ER [10]. BACE1 is a type I membrane protein; it is
synthesized in the ER and then transported to the plasma membrane
along the secretory pathway. During biosynthesis, the N-terminal
ectodomain faces the lumen of the ER while the short C-terminal tail
faces the cytosol. Since the short C-tail has one single lysine residue
we initially thought that, although it was the nascent ER-based form
of the protein to be modiﬁed, the acetylation was still a cytoplasmic
event. However, biochemical assessment as well as mass spectrometry
revealed that themodiﬁed lysine residueswere all in the ectodomain of
the protein. This ﬁnding posed an immediate biochemical challenge: in
order for the reaction to occur, both the donor (acetyl-CoA) and the en-
zyme (acetyltransferase) of the reaction must be available in the lumen
of the organellewhen BACE1 is synthesized. Subsequent efforts resulted
in the identiﬁcation of an ERmembrane acetyl-CoA transporter [15] and
two ER-based acetyltransferases [17].
2.1. The transporter
Acetyl-CoA serves as the common donor of the acetyl group for the
reaction of lysine acetylation (Box 1). Coenzyme A (CoA) is the carrier
of the acetyl group, which is linked to the β-mercaptoethylamine end
of CoA by a high-energy thioester bond. Acetyl-CoA originates from
the break-down of carbohydrates, fatty acids and amino acids.Mamma-
lian cells have three main and distinct pools of acetyl-CoA: a cytosolic/
nuclear pool, amitochondrial pool, and a peroxisomal pool. The cytosol-
ic and nuclear pools are here considered as one because acetyl-CoA can
freely pass through the nuclear pore complex [18]. A fourth and smaller
pool of acetyl-CoA, which depends on active import from the cyto-
sol, also exists in the ER and is essential for ER-based acetylation
(see below). Because of its highly charged structure, acetyl-CoA
cannot cross a lipid bilayer and is completely impermeable to cell
membranes. This obstacle is resolved by the existence of speciﬁc
membrane transporters that ensure continuous supply from both
the mitochondria and the peroxisomes.
Mitochondrial acetyl-CoA is transported to the cytosol as citrate
by the tricarboxylate membrane transport system. Once in the cyto-
sol, citrate is rapidly converted into oxaloacetate by the ATP-citrate
lyase (Acly) releasing acetyl-CoA (Fig. 1). The reaction requires ATP
and free CoA. The oxaloacetate is then converted into pyruvate by
the sequential action of the malate dehydrogenase and malic enzyme
and transported back into the mitochondria by the pyruvate mem-
brane transporter. Here, pyruvate re-enters into the “pyruvate–citrate
cycle” ensuring continuous transfer of acetyl-CoA from the mitochon-
dria to the cytosol [19]. A carnitine acetyltransferase-carnitine acetyl
translocase (CAT) system also appears to contribute to the active
transport of mitochondrial acetyl-CoA into the cytosol [20].Peroxisomal acetyl-CoA is transported to the cytosol as part of differ-
ent pathways, depending on the organism and cell type [21,22] (Fig. 1).
The ﬁrst involves conversion of acetyl-CoA into acetyl-carnitine by the
peroxisomal enzyme carnitine acetyltransferase. Following export from
the peroxisome, acetyl-carnitine can enter the mitochondria for further
metabolism or feed into the cytosolic/nuclear pool of acetyl-CoA
[21,23–25]. Peroxisomal acetyl-CoA can also enter the glyoxylate
cycle to produce succinate, which is subsequently transported to
the cytosol and mitochondria for further metabolism [21]. Finally,
acetyl-CoA can be hydrolyzed within the peroxisome to acetate
and CoA; it has been suggested that this free acetate can be exported
to the cytosol where it is used to generate acetyl-CoA [22,26]. The
mechanisms of acetyl-CoA transport from the peroxisomes to the cy-
tosol are still poorly understood and the relative contribution of the
above pathways in mammals is currently uncertain.
In addition to the conversionof citrate byAcly, cytoplasmic acetyl-CoA
also originates from the condensation of free acetate and CoA by
acetyl-CoA synthetase (AceCS) (Fig. 1). Both Acly and AceCS are also
present in the nucleus, suggesting that acetyl-CoA production can also
occur in the nuclear compartment (independently from the cytosolic
pool), where it regulates histone acetylation and, therefore, gene
expression [27].
The cytosolic pool of acetyl-CoA serves as the donor of the acetyl
group for the reaction of lysine acetylation occurring in the cytosol,
Fig. 1. Biochemical pathways that contribute to cytosolic Acetyl-CoA. Pathways as well as speciﬁc key enzymatic steps are described in the text and in Box 1.
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of acetyl-CoA impedes free passage across the lipid bilayer. Therefore,
if lysine acetylation occurs in the lumen of the ER, a speciﬁc transport-
er must exist in the ER membrane. Alternatively, enzymes responsible
for acetyl-CoA synthesis could grant local production of the metabo-
lite, assuming that its precursors are also available in the lumen of
the ER. However, no evidence for a luminal synthesis of acetyl-CoA
in the ER exists. To address this apparent biochemical obstacle, we
initially assessed whether highly puriﬁed ER vesicles were able to im-
port free acetyl-CoA [10]. The experiments revealed that ER vesicles
were able to import acetyl-CoA in a concentration- and temperature-
dependent fashion, suggesting a carrier-mediated process. Importantly,
acetyl-CoA transport was found to be saturable with an apparent Km of
14 μM[10], which is in the range of cytosolic acetyl-CoA availability and
Km of other acetyl-CoA utilizing enzymes [28–30].
Interestingly, in 1997, ten years before we discovered that lysine
acetylation occurs in the lumen of the ER [10], Kanamori et al. reported
the identiﬁcation of a putative acetyl-CoA transporter in the ER mem-
brane [31]. The gene product, solute carrier family 33 member 1
(SLC33A1)/Acetyl-CoA Transporter-1 (AT-1), was identiﬁed as part of
a screen for the Golgi-resident acetyltransferase responsible for the
O-acetylation of complex gangliosides. Surprisingly, SLC33A1/AT-1
(simply called AT-1 later on) displayed features that were consistent
with a putative ER membrane transporter and appeared to inﬂuence
the acetylation of non-lipid constituents rather than gangliosides. As a
result, the group led by Hirabayashi proposed a possible role of AT-1
as an ERmembrane acetyl-CoA transporter [31,32]. Further biochemical
studies from our laboratory conﬁrmed that AT-1 was indeed the ER
membrane acetyl-CoA transporter (Fig. 2). Importantly, the functional
identiﬁcation of the transporter was achieved by biochemical reconsti-
tution of the transport activity into artiﬁcial liposomes [15].
AT-1 is 549 amino acids long, migrates as a ~60–62-kDa band on
reducing electrophoresis, and is predicted to have nine-to-twelvetransmembrane domains. Finally, it displays an exclusive ER localiza-
tion, which is consistent with its biochemical function [15]. AT-1-
mediated translocation of acetyl-CoA is inhibited with high speciﬁcity
byCoA, suggesting that the CoAmoiety serves as recognition signal [15].
2.2. The acetyl-CoA:lysine acetyltransferases
As with the transporter, the existence of an acetyl-CoA:lysine
acetyltransferase activity in the lumen of the ER was ﬁrst proven with
classical biochemistry. In fact, afﬁnity puriﬁed BACE1 could be acetylat-
ed in vitrowhen radiolabeled acetyl-CoAwas added togetherwith high-
ly puriﬁed ER vesicles. Importantly, acetylation was only observed in
the presence of permeabilized ER vesicles, indicating that the enzymatic
activity resided in the lumen of the organelle [10]. The human genome
was then searched for genes encoding proteins that displayed structural
similarities to the catalytic domain of existing acetyltransferases.
The analysis resulted in the identiﬁcation of two different ER-based
acetyltransferases, which were named ATase1 (also known as camello-
like 2 and N-acetyltransferase 8B) and ATase2 (also known as camello-
like 1 and N-acetyltransferase 8) [17]. The two transferases are 86%
identical at the protein level. Both have one short cytosolic tail, a sin-
gle transmembrane segment and a larger endolumenal domain with
the catalytic activity (Fig. 2) [17]. When separated on gel electrophore-
sis, they have an apparent molecular mass of ~28-kDa and ~25-kDa,
respectively.
ATase1 and ATase2 are members of the camello family, which be-
longs to the GNAT (Gcn5-related N-acetyltransferase) superfamily of
N-acetyltransferases. The GNAT superfamily includes over 10,000
members grouped in more than 12 protein families with diverse cel-
lular functions and substrates [33,34]. Members of this superfamily
share the GNAT (acetyltransferase) domain, which contains four con-
served sequence motifs, known as Motif C, D, A and B (ordered from
N-terminus to C-terminus) [33–35]. Although the homology at the
Fig. 2. Nε-lysine acetylation in the lumen of the ER. A, The ERmembrane transporter AT-1
ensures a continuous supply of acetyl-CoA into the ER lumen while ER-membrane an-
chored acetyltransferases (ATase1 and ATase2) catalyze the transfer of the acetyl group
to seven lysine residues of BACE1. B, Covalent modiﬁcation of the Nε-amino group of a ly-
sine residue by acetylation.
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family, might not be outstanding (3–23% pairwise sequence identity),
the structure of the GNAT/acetyltransferase domain is highly con-
served [34,35]. The GNAT conserved fold contains an N-terminal
beta strand (B1) followed by two alpha helices (H1 and H2), three an-
tiparallel beta strands (B2–B4), a central alpha helix (H3), another
beta strand (B5), a fourth alpha helix (H4) and a ﬁnal beta strand (B6)
[34]. The lowest degree of conservation is found in the N-terminal
motif C (B1–H1) while the strongest is found in motifs D (B2–B3), A
(B4–H3) and B (B5–H4). Together they make the HAT (histone
aceytltransferase) core (Fig. 3) [33,35,36]. Motif A is the most con-
served motif from prokaryotes to eukaryotes and is also present in
p300/CBP and MYST family (named after its founding members:
MOZ, Ybf2/Sas3, Sas2 and Tip60) [37]. It contains the sequence Arg/
Gln-X-X-Gly-X-Gly/Ala that is important for acetyl-CoA recognition and
binding, establishing most of the direct contacts to bound CoA. Remark-
ably, in spite of the high degree of sequence identity, the alignment of
ATase1 and ATase2 sequences revealed three non-conservative amino
acid substitutions inside theHAT core. Further studies are required to de-
termine any functional consequences of these substitutions. Interesting-
ly, two of these substitutions are located inside Motif A and one of them
is in the sequence that makes up direct contact to bound CoA (Fig. 3).
These differences may have important consequences for the kinetics of
the enzymatic activity and, perhaps, could explain the high degree ofselectivity as well as the lack of off-site effects displayed by ATase1/
ATase2 inhibitors [38].
ATase1 and ATase2 are differentially expressed in a variety of immor-
talized as well as primary cells [38]. Both in themouse and human brain,
they appear to bepreferentially—if not exclusively—expressed inneurons
[38]. Finally, they are up-regulated in patients affected by Alzheimer's
disease [38], further supporting a possible disease-association.
CML2 (the gene encoding ATase1) and CML1 (the gene encoding
ATase2) appear to be the result of a gene duplication event that oc-
curred after the ape-Old World monkey split [39]. Although no disease
association has been reported, several single nucleotide polymorphisms
(SNPs) have been identiﬁed on both genes in the human population.
Particularly, one SNP (accession no. rs4852974) on ATase1 generates a
stop codon in themiddle of the acetyl-CoA:lysine acetyltransferase cat-
alytic domain and is predicted to inactivate the enzyme. The SNP seems
to be present in less than 2% of the general population.Whether this re-
sults in decreased ATase activity is unknown. Also unknown is the bio-
logical relevance of this apparent inactivation.
It is likely that ATase1 and ATase2 are not the only ER-based
acetyltransferases. Interestingly, calreticulin, an ER luminal protein
that is mostly known as a Ca+2-binding chaperone, appears to have
acetyl-CoA:lysine acetyltransferase activity in vitro [40]. Whether
calreticulin retains acetyltransferase activity in vivo remains to be
determined. Also to be determined are its potential substrates. However,
considering the number of ER-resident and -transiting proteins that in-
teract with calreticulin in the ER lumen, this potential acetyltransferase
activity could have large impact.
In vitro assessment revealed that ATase1, but not ATase2, un-
dergoes autoacetylation in one or more lysine residues [17]. The bio-
logical signiﬁcance of this different behavior is still unclear. In the case of
other acetyltransferases, the autoacetylation event has been described
either as part of an allosteric mechanism that regulates the activity of
the acetyltransferase or as part of the catalytic signature of the
transferase (see below in the Conclusive remarks and unresolved
questions section). The allosteric switch is meant to regulate the activ-
ity of the acetyltransferasewithout involving transcription/translation of
the enzyme. In fact, when “hypo-acetylated” the enzyme displays re-
duced activity, whilewhen “hyper/auto-acetylated” the enzyme displays
increased activity [41,42]. This scenariowould be consistentwith the fact
that ATase1 appears to act as a constitutive formof acetyltrasferasewhile
ATase2 appears to be tightly controlled at the transcriptional level [38].
2.3. The disposing machinery
To further study the role of lysine acetylation in the metabolism of
nascent BACE1, wemutated the seven lysine residues that are normally
acetylated in the native protein into alanine, arginine or glutamine. The
Lys-to-Ala and Lys-to-Arg substitution generates “loss-of-acetylation”
mutants whereas the Lys-to-Gln substitution generates a “gain-of-
acetylation”mutant form of BACE1. The use of the above mutants re-
vealed that the acetylated intermediates of BACE1 are able to reach
the Golgi apparatus and complete maturation while the non-acetylated
intermediates are retained in the ER Golgi Intermediate Compartment
(ERGIC) [10]. Although efﬁciently synthesized in the ER and not able to
reach the Golgi apparatus, the “loss-of-acetylation”mutants did not ap-
pear to accumulate in the ERGIC or to be disposed of by the proteasome
machinery [10]. This observation suggested that an alternative pathway
was responsible for the disposal of non-acetylated BACE1 intermediates.
Subsequent studies revealed that proprotein convertase subtilisin kexin
type 9 (PSCK9)/neural-apoptosis-regulated convertase 1 (NARC-1) was
an essential component of the disposing machinery [14] (Fig. 4).
PCSK9/NARC-1 is a member of the subtilisin (S8) family of serine
proteases [43,44]. More speciﬁcally, PCSK9/NARC-1 is part of the S8A
subfamily, which so far includes only two members, PCSK9/NARC-1 it-
self and site-1 protease (S1P), known to regulate the processing and
consequent activation of several ER-based transcription factors [45].
Fig. 3. Alignment of the primary sequence of the ATases HAT core with prominent members of the GNAT superfamily. A, Sequence logo of the GNAT domain proﬁle available at
PROSITE (Database of protein domains, families and functional sites (http://prosite.expasy.org); PS51186). The sequence logo was generated after multiple sequence alignment
of 660 UniProtKB/Swiss-Prot true positive hits. The consensus sequence of the GNAT domain can be read from the top of the stacks. The height of each letter is proportional to
the frequency of the corresponding amino acid at the indicated position in the alignment. B, Primary sequence alignment of the HAT core highly conserved motifs of ATase1
(NAT8B_HUMAN, Q9UHF3), ATase2 (NAT8_HUMAN, Q9UHE5) and other members of the GNAT superfamily, including Lysine acetyltransferase 2A also known as hGCN5
(KAT2A_HUMAN, Q92830), Lysine acetyltransferase 2B also known as PCAF (KAT2B_HUMAN, Q92831) and aralkylamine N-acetyltransferase (AANAT) also known as SNAT
(SNAT_HUMAN, Q16613). The ﬁrst and last columns indicate the amino acid position from the corresponding full sequence. The numbers in parenthesis between the conserved
motifs indicate the length of the omitted sequence. The alignment was performed using the Clustal Omega multiple sequence alignment program (http://www.ebi.ac.uk/Tools/
msa/clustalo). In red are highlighted fully conserved residues from the consensus sequence indicated in A. The presence of the second most frequently occurring consensus
amino acid is indicated in yellow. The “:” (colon) indicates conservation between groups of strongly similar properties (scoring>0.5 in the Gonnet PAM 250 matrix) after alignment
of the ATase1 and ATase2 sequences with the GNAT consensus sequence. The “.” (period) indicates conservation between groups of weakly similar properties (scoring=b0.5 in the
Gonnet PAM 250 matrix) after alignment of the ATase1 and ATase2 sequences with the GNAT consensus sequence. The alignment of ATase1 and ATase2 sequences revealed the
presence of non-conservative amino acid substitutions in motifs A and D (arrows). The box in Motif A encloses the residues that have been shown to be important for
acetyl-CoA recognition and binding in other members of the GNAT superfamily.
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catalysis to generate a shorter form of ~65-kDa [46,47]. PCSK9/NARC-1
has received great attention since the discovery that mutations in the
Pcsk9/Narc1 gene are associated with hypercholesterolemia. The fact
that PCSK9/NARC-1 can regulate the degradation of the low-density li-
poprotein (LDL) receptor (LDLR) has caused additional excitement as
possible down-regulation or biochemical inhibition of PCSK9/NARC-1
might serve as an alternative approach for reducing hypercholes-
terolemia. In fact, low levels or activity of PCSK9/NARC-1 would
lead to increased expression of LDLR in the liver and increased uptake/
degradation of circulating LDL [43,44].
Although the exact role of PCSK9/NARC-1 in LDLR metabolism is still
uncertain, early work showed that one of its essential functions is to reg-
ulate the disposal of LDLR in a “post-ER compartment” while transiting
along the secretory pathway [48,49]. The “post-ER compartment”mech-
anism was brieﬂy put aside by evidence that PCSK9/NARC-1 could also
degrade cell-surface LDLR following secretion in the conditioned media
[50–52]. However, recent work has spurred new interest in the “post-ER
compartment”mechanism [53]. The fact that PCSK9/NARC-1 could affect
the levels of the nascent form of LDLR in a post-ER compartment while
trafﬁcking along the secretory pathway [48,49] stimulated our own in-
terest. The possible involvement of PCSK9/NARC-1 in the disposal of
non-acetylated intermediate forms of BACE1 in the ERGICwas addressed
by a combination of biochemical andmolecular biological approaches. In
particular, over-expression of PCSK9/NARC-1 in cultured cells decreased
the levels of BACE1whereas siRNA-mediated down-regulation of PCSK9/
NARC-1 achieved the opposite results [14]. Finally, the levels of BACE1
were found to be increased in the brain of PCSK9/NARC-1 knockout ani-
mals [14]. Importantly, down-regulation of PCSK9/NARC-1 increased the
levels of the “loss-of-acetylation”mutant forms of BACE1 but not those of
the “gain-of-acetylation”mutants, suggesting that PCSK9/NARC-1 might
work in concert with the ER-based acetylationmachinery to regulate the
disposal of BACE1 non-acetylated intermediates [14]. This conclusion is
further supported by the observation that, similarly to BACE1, thenascent ER-form of LDLR is acetylated [14], suggesting a common func-
tion for the serine protease.
It is also worth mentioning that the promoter region of Pcsk9/Narc1
contains a sterol regulatory element (SRE). As a result, the mRNA levels
of PCSK9/NARC-1 are up-regulated by SRE-binding proteins (SREBPs),
ER membrane-based transcription factors that control both biosynthesis
and uptake of cholesterol [54,55]. As a consequence, the expression of
PCSK9/NARC-1 is down-regulated by increased cellular cholesterol con-
tent [56], and upregulated by HMG-CoA inhibitors (also known as
“statins”), which reduce cholesterol content [57]. These results are par-
ticularly important considering that several aspects of cholesterol me-
tabolism have been associated with Alzheimer's disease [58], including
the fact that increased cellular levels of cholesterol (which are predicted
to decrease PCSK9/NARC-1-mediated disposal of BACE1) increase Aβ
generation, whereas reduced levels of cholesterol (which are predicted
to increase PCSK9/NARC-1-mediated disposal of BACE1) reduce Aβ
generation.
Although initially studied for its implication in LDLR metabolism,
it is now evident that PCSK9/NARC-1 “does”more than just regulating
LDLR levels. In fact, in addition to BACE1 [14] and APP [15], it also reg-
ulates the disposal of other cell-surface membrane proteins [59,60]
and perhaps secreted proteins as well [61], suggesting a more global
function. Indeed, a recent proteomic study identiﬁed more than 300
proteins that are inﬂuenced by PCSK9/NARC-1 activity [62]. The list
includes cell-surface proteins as well as intracellular proteins, proteins
involved in folding and post-translational modiﬁcation in the early se-
cretory pathway, proteins involved in vesicle and organelle transport,
cytoskeleton as well as cell-adhesion proteins. This global impact of
PCSK9/NARC-1 was also demonstrated by two microarrays studies,
which implicated this serine protease in many biological pathways
[63,64].
We initially reported that inhibition of the proteasome machinery
did not appear to affect the disposal of the “loss-of-acetylation”mutant
forms of BACE1 [10]. However, recently Gong et al. have proposed the
Fig. 4. Schematic view of BACE1 acetylation. Nascent BACE1 is transiently acetylated in the lumen of the ER by ATase1 and ATase2. If acetylated, nascent BACE1 can reach the Golgi
apparatus and complete maturation. In contrast, non-acetylated BACE1 is retained and degraded in the ERGIC. The ER-based acetylation also requires translocation of acetylCoA
from the cytosol into the lumen of the ER by the ER membrane transporter AT-1. The acetyl group is shown as a red circle.
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ligase complex, suggesting that the ubiquitin–proteasome systemmight
still be involved with the clearance of non-acetylated species of BACE1
[65]. The ubiquitylation of BACE1 is somewhat speciﬁc and seems to
occur on some of the seven lysine residues that are acetylated [65]; this
could potentially explain why acetylated BACE1 intermediates are resis-
tant to proteasome degradation [10]. Whether there is cross-talk be-
tween PCSK9/NARC-1 and SCFFbx2-E3 ligase remains to be assessed. In
fact, PCSK9/NARC-1 is a serine protease aswell as a chaperone-like pro-
tein, while Fbx2 is typically involved in the recognition and binding of
high-mannose oligosaccharides onmisfolded/unfolded ER luminal pro-
teins, which are subsequently targeted for proteasome-dependent dis-
posal (see also later). Another issue that will also need further
investigation is how the Fbx2-SCF ubiquitin ligase complex can have ac-
cess to the ectodomain of BACE1; in fact, the former is in the cytosol
while the latter is in the lumen of the ER. It is likely that nascent
non-acetylated BACE1 might need to be “pre-processed” and retro-
translocated to the cytosol before becoming a substrate of the Fbx2-SCF
ubiquitin ligase complex, as described for other Fbx2-SCF substrates [66].
3. A novel mechanism for quality control and/or ERAD?
The essential information for the correct assembly of membrane
and secreted proteins synthesized in the ER is already present in
their primary amino acid sequence. However, the efﬁciency of folding
itself is ensured and enhanced by ER-resident proteins that act as
chaperones and/or modifying enzymes. Chaperones assist in the fold-
ing by ensuring safe passage of the nascent protein chain through the
ER membrane, by retrieving and preventing aggregation of incorrect-
ly folded protein intermediates, and—in some cases—by protectingthe nascent polypeptide from interacting with potential ligands in
the ER [67,68]. Chaperones can be solely restricted to the ER, can travel
through the secretory pathway together with their substrates or, in
some cases, be secreted to the extracellularmilieuwith their immediate
substrates [67–69]. The large family of ER chaperones includes heat-
shock proteins such as BiP, calreticulin, calnexin and the receptor asso-
ciated protein (RAP). In contrast to chaperones, modifying enzymes
typically ensure correct folding by completing the information already
contained in the primary amino acid sequence. Some examples are
the protein disulﬁde isomerase (PDI), which catalyzes the oxidation of
free SH groups of paired cysteine residues to form disulﬁde bonds
(-CH2\S\S\CH2-), and the oligosaccharyltransferase (OST), which
transfers a preformed “core” oligosaccharide from a glycolipid donor,
the dolichol-P-P-(GlcNAc)2(Man)5(Glc)3, to an asparagine residue in
the consensus sequence Asn-X-Ser/Thr of the nascent glycoprotein. Al-
though the above are examples of permanent covalent modiﬁcations,
there are also transient modiﬁcations that are only meant to recognize
and salvage incorrectly folded protein intermediates. This is the case
of the UDP-glucose:glycoprotein glucosyltransferase (UGGT), which at-
taches one glucose residue to improperly folded nascent glycoproteins
and regulates its interaction with the lectin chaperone calnexin [70,71].
The above chaperones andmodifying enzymes not only ensure ﬁdel-
ity of the “protein code” by assisting nascent polypeptides in assuming
the right conformation, which is necessary to their function, but also se-
quester incorrectly folded intermediates that have failed quality control
(QC). These are generally retained in the ER and directed toward the
ER associated degradation (ERAD). Incorrectly folded polypeptides that
are disposed of by the ERAD are typically retro-translocated to the cyto-
sol and sent to the proteasome for disposal but can also aggregate (in the
cytosol or in the ER itself) to form protein inclusions. The fate of the
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that failed QC, thus preventing their otherwise toxic functions (this
seems to be the case for the cytoplasmic aggregates called “aggresomes”)
or can be digested through autophagic-like mechanisms (see below)
[68,72–76]. However, under certain conditions, protein aggregates can
be overwhelming for the cell and become toxic themselves. Misfolded
protein intermediates can also bypass the above more classical ERAD
and be directed to the Golgi apparatuswhere they are retained or direct-
ed to the lysosomes for ultimate degradation [68].
3.1. To protect the good ones
The use of the acetylationmutants revealed that the acetylated inter-
mediates of BACE1 are able to reach the Golgi apparatus and complete
maturation while the non-acetylated intermediates are retained in the
ERGIC [10]. In addition, the down-regulation of PCSK9/NARC-1 only in-
creased the levels of the “loss-of-acetylation” mutant, suggesting that
some sort of selection takes place [14]. These features are reminiscent
of a QC event where certain biosynthetic intermediates are selected for
“free passage” across the secretory pathway while others (presumably
unfolded/misfolded intermediates) are not (see Fig. 4). Although the
possible connection between lysine acetylation in the ER and QC still
needs to be carefully evaluated, this possibility is supported by the
“chaperone-like” activity of the acetyltransferases [17]. Perhaps, the
ATases can only recognize and acetylate correctly folded intermediates.
Perhaps, the Nε-lysine acetylation provides away to “lock” the acetylated
(correctly folded) intermediates to the transferases protecting them
from PCSK9/NARC-1 mediated disposal. The locking mechanisms would
explain why all seven acetylated lysine residues in BACE1 are located
on the same face of the protein [10]. Perhaps, the release of the ATases
[17] togetherwith the deacetylation of BACE1 that occurs in the Golgi ap-
paratus [10] serves to “restore” the original “protein code” allowing ﬁnal
maturation and transport to the cell surface. Perhaps, the ATases do not
simply serve to recognize already folded protein intermediates but ac-
tively participate in the folding itself. In the case of BACE1, the acetylated
lysine residues are clustered in areas that are characterized by low-
electron density (and intrinsic conformational ﬂexibility). This structural
ﬂexibility appears to be essential for the catalytic activity [77–79] as well
as for the natural “shedding” [80] of the enzyme. It is possible that the
Nε-lysine acetylation—by neutralizing the positive charges of the lysine
residues—serves to stabilize and facilitate the folding of kinetically unfa-
vorable areas of the nascent protein [10]. Perhaps, the “stabilization” and
“locking” mechanisms delineated above are intimately connected to
achieve greater efﬁciency while processing large quantities of nascent
membrane and secreted proteins in the ER. Although we recognize that
the above “perhaps” still need to be biochemically proven, our current in-
formation appears to preclude other possibilities. This view is also
supported by the fact that BACE1 is not alone; in fact, other membrane
proteins undergo the same transient post-translational modiﬁcation
[14–16].
3.2. What if it fails?
If the ER-basedNε-lysine acetylationmachinery is an essential formof
post-translational regulation of nascent proteins, we would expect the
global failure of the ER-based acetylation to lead to cellular disaster. The
down-regulation of the two transferases, ATase1 and ATase2, did not re-
sult in signiﬁcant cell toxicity [17]. However, it is likely that the ER has
more than just two acetyltransferases (discussed above); it is also likely
that the transferases share (at least in part) their substrates allowing
for one enzyme to compensate for the lack of the other(s). In contrast
to theATases, the down-regulation of AT-1 resulted inmassive andwide-
spread cell death, indicating that the translocation of acetyl-CoA into the
ER lumen is an essential cellular function [15,81]. This conclusion is
strongly supported by the fact that AT-1 is mutated in patients affected
by autosomal dominant spastic paraplegia-42 (SPG42) [82].SPG42 is part of the highly heterogeneous family of hereditary spastic
paraplegias (here collectively called SPGs). The clinical heterogeneity
probably reﬂects the genetic complexity of the disease. A recent list of
genes and loci implicated with SPGs has been reported by Salinas et al.
[83]. SPGs are generally divided into two groups: uncomplicated and
complicated. Uncomplicated SPGs are typically characterized byprogres-
sive bilateral spasticity and peripheral neuropathy; urinary symptoms
andmild cognitive decline are also present in a large number of patients.
The onset of the disease varies greatly from early childhood to as late as
70 years of age. Themain pathological feature of uncomplicated SPGs is a
progressive degeneration of motor axons of the corticospinal tract in the
absence of evident muscle pathology. Loss of volume of the corpus
callosum andmemory-forming areas of the brain, as well as disseminat-
ed lesions of cerebral white matter, have also been reported [83,84].
Complicated SPGs are characterized by the fact that the lower limb spas-
ticity is accompanied by other features such as severe mental retarda-
tion, dementia, epilepsy, cerebellar ataxia, amyotrophy, retinopathy,
glaucoma, deafness and icthyosis [83,84].
Enlarged ER sheets and tubules as well as generalized defects of the
ER network constitute a commonmorphological feature of SPG neurons
(reviewed in [85]). Importantly, the vast majority of mutations found in
SPGs are concentrated in genes encoding proteins that are localized in
the ER and ERGIC, function at the ER-to-Golgi interface or are overall in-
volved in ER network organization, membrane trafﬁcking, and axonal
transport of macromolecules and other cargoes (reviewed in [83,85]).
This ﬁnding should be viewed together with the fact that the earliest
andmost striking changes observed in SPG patients are always concen-
trated in the long axons of descending and ascending spinal neurons. In
humans, these processes canmeasure up to onemeter in length. As a re-
sult of their morphology, they are heavily dependent on membrane
trafﬁcking, rapid axonal transport of cargo molecules from the ER to
the plasma membrane and active cytoskeletal organization. A defect
in the above events is likely to disrupt their function and lead to degen-
eration. Interestingly, haploinsufﬁciency or leaky mutations associated
with SPGs only cause defects/degeneration of neurons, further stressing
the strong dependence of neuronal cells to the above events [86,87]. Al-
though ER network organization, membrane trafﬁcking, and transport
of macromolecules are essential and common features of every cell,
neurons are simplymore dependent on them. However, less dependence
does not mean no dependence! In fact, a ~95% decrease in AT-1 levels
causedmassive death of cultured cells under ex vivo conditions [15]. Fur-
thermore, down-regulation of AT-1 in the zebraﬁsh increased embryonic
lethality and caused a curved-shaped tail phenotype in the surviving an-
imals, as well as defective axonal growth of spinal cord neurons [82]. The
striking phenotype caused by the down-regulation of AT-1 under both ex
vivo [15] and in vivo [82] conditions indicates that a constant inﬂux of
acetyl-CoA into the lumen of the ER is an essential cellular function
(discussed later).
Mutations in AT-1 have also been identiﬁed in ﬁve patients affected
by a complex autosomal-recessive syndrome characterized by psycho-
motor retardation and severe developmental delay. The patients, who
displayed brain atrophy, cerebellar hypoplasia, hypomyelination, con-
genital chataracts, hearing loss, andmulti-organ failure, died premature-
ly within the ﬁrst 5 years of their life [88]. In contrast to SPG42 patients,
whowere heterozygous for themutation [82], the abovewere all homo-
zygous [88]. The above patients also displayed low serum copper and ce-
ruloplasmin [88]. However, reassessment of one of the above ﬁve
patients identiﬁed an additional mutation in the copper chaperone for
superoxide dismutase (CCS) [89], suggesting that the phenotype might
be complicated by the co-presence of more than one mutation.
3.3. Regulation of autophagy/ERAD(II) by the ER-based acetylation
machinery
A close assessment of themodalities of the cell death associatedwith
the down-regulation of AT-1 in culture revealed that cells initially
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creasing the size of the ER tubules [15]. This is then followed by the for-
mation of autophagosomes in close proximity of the ER membrane,
suggesting that the ER membrane itself participates in the formation
of the autophagic elements. If the down-regulation of AT-1 persists,
the entire ER breaks down into autophagosomes and ultimately the
cell dies by autophagic cell death [15]. Importantly, before widespread
digestion of intracellular organelles (ﬁnal autophagic cell death) the
ER is the only organelle that appears to be affected. The above observa-
tion clearly indicates that the continuous supply of acetyl-CoA into the
ER lumen is an essential feature of this organelle; they also indicate
that autophagic digestion of ER tubules is the preferential strategy to
deal with the failure of the ER-based acetylation machinery.
Autophagy is a cellular process that allows turnover and/or degrada-
tion of subcellular components, which are initially engulfed in double-
membrane structures and then diverted toward active lysosomes for
ﬁnal degradation. This process can be part of typical “house-keeping”
activities that dispose of unwanted proteins or excessive membranes;
it can also serve to ensure supply of nutrients during starvation or to
clear the organism of unwanted cells during development [76,90–93].
As described above, the ER has mechanisms in place that ensure correct
folding of secreted/membrane proteins. When these fail, unwanted
(unfolded/misfolded) proteins are typically degraded by the proteasome
as part of ERAD. However, the proteasome preferentially degradesmono-
meric proteins that are unfoldedprior to retro-translocation across the ER
membrane [68]. Large protein aggregates are mostly dealt with by
expanding the ER and activating autophagy. The autophagic process al-
lows the cell to counterbalance the ER expansion and dispose of the pro-
tein aggregates at the same time [73–75,94]. This process is still part of
ERAD and the terms ERAD(I) and ERAD(II) have also been used to differ-
entiate the ubiquitin/proteasome process from the autophagic process,
respectively [95]. Therefore, autophagy must be seen as an essential
cellular function that ensures disposal of unwanted material. This is par-
ticularly important for neurons where a high threshold for ER stress
(discussed above) and inherent cellular features require a continuous
and efﬁcient way to dispose of protein aggregates [92,96–99]. Obviously,
if unchecked, autophagy can become terminal (autophagic cell death;
also referred to as type II cell death to differentiate it from apoptosis,
which is referred to as type I cell death). Both ERAD(I) and ERAD(II) are
under the control of the unfolded protein response (UPR), a complex
ER-based signaling machinery that corrects possible imbalances that re-
sult in ER stress and adjusts the ability of the organelle to cope with the
accumulation of unfolded/misfolded protein intermediates [68,100–102].
That the ER-based acetylation machinery is intimately linked to the
UPR and ERAD(II) in the ER is supported by four main recent ﬁndings.
First, a large number of ER-resident proteins involved with folding and
disposal of unfolded/misfolded protein intermediates is acetylated in
the lumen of the ER [16]. Second, already known and well characterized
ER stress inducers increase the inﬂux of acetyl-CoA into the ER lumen by
up-regulating the expression of AT-1 [81]. Third, the up-regulation of
AT-1 during ER stress was linked to one of the three main branches of
theUPR, speciﬁcally to the inositol-requiring protein-1 (IRE1)-dependent
signaling pathway [81]. IRE1 is an ER-membrane bound protein that
whenactivated, as a result of ER stress, removes a small fragment (intron)
from the mRNA of X-box binding-1 (XBP1). The process requires the
endoribonuclease activity of IRE1 and the ligase activity of an unknown
ligase [102,103]. The product of the spliced version of XBP1 (XBP1s) is a
potent transcriptional activator of UPR target genes that promote ERAD
of unfolded/misfolded protein intermediates and ER biogenesis [104].
Fourth, AT-1 was shown to regulate the activation of autophagy down-
stream of XBP1 itself [81]. Therefore, the inﬂux of acetyl-CoA into the
ER lumen is a novel and essential feature of the UPR and appears to con-
trol the ability of the ER to recognize and select correctly folded protein
intermediates (as observed with BACE1), and dispose of unfolded/
misfolded protein aggregates through the regulation of autophagy/
ERAD(II). At the mechanistic level, the regulation of ERAD(II)involves intraluminal acetylation of the autophagy protein Atg9A
[81], which might act as an ER-based “sensor” for the acetylation status
of the ER (Fig. 5). Indeed, acetylation of Atg9A prevents the induction of
autophagy whereas the deacetylation (or lack of acetylation) has the
opposite effect [81]. A similar regulatory function of the Nε-lysine
acetylation has also been observed with the cytosolic members of
the autophagic machinery, speciﬁcally Atg5, Atg7, Atg8 and Atg12
[105,106].
It must be noted that the activation of the “ER stress signaling” is both
a physiologic and pathologic event. Cells can experience transient pe-
riods of ER stress as part of their activity [107–110]. As discussed
above, due to their speciﬁc functions, neurons may have to cope with a
substantial physiological burden and, as a result, have higher basal levels
of ER stress. This could potentially explain why amutation in AT-1 is pri-
marily associated with a disease of the nervous system. However, B cells
also experience reorganization and expansion of the ER and activation of
the UPR when they differentiate into immunoglobulin secreting plasma
cells [111]. The ultimate purpose is to ensure the biosynthesis and secre-
tion of a large quantity of correctly folded immunoglobulins [111,112].
Interestingly, the differentiation process of B cells into plasma cells is
also accompanied by activation of XBP1 signaling and up-regulation of
AT-1 [113]. Therefore, AT-1 does not only respond to ER stress-inducing
experimental drugs, which are largely non-physiologic, but also to
“naturally” occurring conditions that require induction of the ER
stress machinery.
4. Conclusive remarks and unresolved questions
Although “young”, the ER-based acetylation machinery is rapidly
emerging as a major component of normal ER functions and is poised
to grow in importance aswe further delineate its impact on physiologic
and pathologic events. As we learn more, several currently unresolved
questions will need to be addressed. For example:
What is the purpose of the ER-based acetylation? Studies performed
with BACE1 indicate that the Nε-lysine acetylation of the nascent
protein might serve to distinguish between correctly folded and
unfolded/misfolded protein intermediates. Although it needs to
be proven, a similar mechanism might be in place for other
ER-transiting proteins, which need to move out of the ER along
the secretory pathway. However, why acetylate ER-resident
proteins, which are not supposed to leave the organelle? Is there a
similar mechanism in place for ER-resident proteins? Perhaps, in the
case of ER-resident proteins the acetylation inﬂuences activity/
function of the proteins rather than their ability to leave the organ-
elle. It is also possible that lysine acetylation is necessary for the
assembly of kinetically unfavorable (disordered?) regions of the na-
scent polypeptide. This scenario could be tested by analyzing
the structural signature—when available—of recently identiﬁed
ER-resident and -transiting proteins that undergo acetylation [16].
Finally, it is highly possible that the cell might have more than one
reason to acetylate nascent proteins in the ER lumen.
How many ATases are in the ER? At this point, it is evident that the
ER has more than two acetyltransferases. Although some overlap is
possible, it is likely that they have different substrates. Identiﬁcation
of the other ATases aswell as their immediate substrateswill help us
target the acetylation machinery for therapeutic purposes. ATase1
and ATase2 are attractive targets for Alzheimer's disease therapeu-
tics [17,38]. It is likely that other ATases might represent viable tar-
gets for other diseases.
What is the catalytic signature of the ATases? Most of the known
acetyltransferases employ two different catalytic mechanisms: the
ternary complex and the ping-pong mechanism [114] (Fig. 6). The
Fig. 5. Regulation of the inﬂux of acetyl-CoA into the ER lumen as part of the UPR. The constant inﬂux of acetyl-CoA into the ER lumen is required to control the induction of
autophagy/ERAD(II) as part of the UPR. Speciﬁcally, AT-1 acts down-stream of IRE1/XBP1 signaling. If the inﬂux of acetyl-CoA is maintained, ERAD(II) helps to eliminate unwanted
unfolded/misfolded aggregates without inducing cell death (A). However, if the inﬂux is not maintained, programmed Type II (autophagic) cell death is activated (B). The
autophagy protein Atg9A seems to act as a “sensor” for the acetylation status of the ER.
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group from the donor (acetyl-CoA) to the acceptor lysine residue.
This process requires the enzyme to interact and bind both the
donor and the acceptor at the same time (hence, ternary complex).
In contrast, the ping-pongmechanism involves initial transfer of the
acetyl group from the donor (acetyl-CoA) to the enzyme, which be-
comes acetylated. The intermediate acetylated enzyme will then
transfer the acetyl group to the acceptor lysine residue. Therefore,
this process requires the acetyltransferase to interact separately
with the donor and the acceptor and to act as an acetylated interme-
diate species (hence, ping-pong). These mechanistic differences are
very important because different mechanisms imply different clas-
ses of inhibitors and different forms of regulation [114].
If there are acetyltransferases, are there deacetylases as well? Our
initial studies with BACE1 indicated that the nascent protein is
normally acetylated in the lumen of the ER and then deacetylated
in the lumen of the Golgi apparatus [10]. Indeed, in vitro biochemical
assessment revealed that the Golgi apparatus possess deacetylase ac-
tivity [10]. Importantly, the activity was found to reside in the lumen
of the organelle [10]. However, computer-based searches for possible
candidates have—so far—failed to yield solid candidates, suggesting
that “more traditional” protein puriﬁcation approaches will be re-
quired to ensure the identiﬁcation of another piece of this puzzle.
Similar strategiesmight also be necessary to determinehow transient
acetylation/deacetylation is achieved for ER-resident proteins.Can AT-1 be targeted for therapeutic purposes? Initial studies indi-
cate that AT-1 is essential for cell viability [15,82]. Indeed, down-
regulation of AT-1 in mammalian cells triggers the activation of
the autophagic machinery and results in widespread type I
(autophagic) cell death [15,81]. As such, we should predict
AT-1 not to be a viable target. However, what is toxic for normal
cells might not be as toxic for sick cells. Indeed, mice expressing
a mutant form of the Cu,Zn superoxide dismutase (SOD1) linked
to amyotrophic lateral sclerosis (ALS) beneﬁt from an excessive
activation of the autophagic machinery [115,116]. This appears
to be due to a more efﬁcient removal of toxic protein aggregates.
Perhaps, a balance between the rate of protein aggregates for-
mation and the rate of autophagy-mediated removal of the ag-
gregates must be ensured. As such, excessive autophagy would
be deleterious in a normal cell with normal levels of protein ag-
gregates, but beneﬁcial in a “sick” cell with excessive formation/
accumulation of protein aggregates. Importantly, the protective
effect of a “hyper-active” autophagic machinery in the above
ALS-like model was achieved by down-regulating XBP1 [115,116],
which appears to act through AT-1 itself [81]. Therefore, AT-1
might be a possible target for therapeutics, albeit only in a selected
group of patients.
How is the cross-talk between AT-1 and the autophagic machinery
ensured? Recent results indicate that the inﬂux of acetyl-CoA into
the ER lumen is “sensed” by Atg9A, the only membrane bound
Fig. 6. Schematic view of the two main catalytic mechanisms employed by acetyl-CoA:lysine acetyltransferases. Description is in the text.
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known. Perhaps the acetylation status of Atg9A regulates its trafﬁck-
ing to the Golgi apparatus and the consequent formation of the
“autophagic membrane”. Or, perhaps, the acetylation status of
Atg9A affects its ability to interact with the other elements of the
autophagic machinery.
Is the proteasome machinery involved? How can we reconcile the
fact that the disposal of non-acetylated BACE1 mutants is not affect-
ed by proteasome inhibitors [10] with the fact that the lysine resi-
dues that are acetylated appear to be necessary for the in vitro
ubiquitylation of BACE1 by the Fbx2-SCF ubiquitin ligase complex
[65]? Are these two mechanisms related? Or are they meant to rec-
ognize different intermediate species of the nascent protein?
Although many questions remain to be answered, one thing is
certain: what was once a cytosolic and nuclear event is now an essen-
tial component of ER functions. Dissection of the biochemistry that
governs the ER-based acetylation machinery will certain lead us to a
better understanding of fundamental biological events that inﬂuence
human physiology and pathology.Acknowledgements
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